Calcineurin Inhibitors

• 

  Subject Areas on Research

  • A Novel Resistance Pathway for Calcineurin Inhibitors in the Human-Pathogenic Mucorales Mucor circinelloides. 
  • A calcineurin-dependent transcriptional pathway controls skeletal muscle fiber type. 
  • A phase II/III randomized, multicenter trial of prednisone/sirolimus versus prednisone/ sirolimus/calcineurin inhibitor for the treatment of chronic graft-versus-host disease: BMT CTN 0801. 
  • A protein encoded within the Down syndrome critical region is enriched in striated muscles and inhibits calcineurin signaling. 
  • Acute graft-versus-host disease: are we close to bringing the bench to the bedside? 
  • Antifungal drug resistance evoked via RNAi-dependent epimutations. 
  • CARHSP1 is required for effective tumor necrosis factor alpha mRNA stabilization and localizes to processing bodies and exosomes. 
  • CT-039 Health-Related Quality of Life Following Allogeneic Hematopoietic Stem Cell Transplantation With Omidubicel Versus Standard Umbilical Cord Blood. 
  • Calcineurin in fungal virulence and drug resistance: Prospects for harnessing targeted inhibition of calcineurin for an antifungal therapeutic approach. 
  • Calcineurin inhibition or mutation enhances cell wall inhibitors against Aspergillus fumigatus. 
  • Calcineurin inhibition with systemic FK506 treatment increases dendritic branching and dendritic spine density in healthy adult mouse brain. 
  • Calcineurin inhibitor agents interact synergistically with antifungal agents in vitro against Cryptococcus neoformans isolates: correlation with outcome in solid organ transplant recipients with cryptococcosis. 
  • Calcineurin inhibitor withdrawal after renal transplantation with alemtuzumab: clinical outcomes and effect on T-regulatory cells. 
  • Calcineurin is required for Candida albicans to survive calcium stress in serum. 
  • Calcineurin is required for hyphal elongation during mating and haploid fruiting in Cryptococcus neoformans. 
  • Calcineurin is required for pseudohyphal growth, virulence, and drug resistance in Candida lusitaniae. 
  • Calcineurin orchestrates dimorphic transitions, antifungal drug responses and host-pathogen interactions of the pathogenic mucoralean fungus Mucor circinelloides. 
  • Calcineurin promotes infection of the cornea by Candida albicans and can be targeted to enhance fluconazole therapy. 
  • Calcineurin signaling in human cardiac hypertrophy. 
  • Calcineurin. Structure, function, and inhibition. 
  • Cell biology. A fungal Achilles' heel. 
  • Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes. 
  • Cryptococcus neoformans in organ transplant recipients: impact of calcineurin-inhibitor agents on mortality. 
  • Cryptococcus neoformans isolates from transplant recipients are not selected for resistance to calcineurin inhibitors by current immunosuppressive regimens. 
  • Differential regulation of calcineurin isoforms in transplant patients: a new look at an old problem. 
  • Effect of Early Everolimus-Facilitated Reduction of Tacrolimus on Efficacy and Renal Function in De Novo Liver Transplant Recipients: 24-Month Results for the North American Subpopulation. 
  • Effects of Sofosbuvir-Based Hepatitis C Treatment Regimens on Calcineurin Inhibitor Dosing in Liver and Kidney Transplant Recipients. 
  • Ergosterol biosynthesis inhibitors become fungicidal when combined with calcineurin inhibitors against Candida albicans, Candida glabrata, and Candida krusei. 
  • Evolutionarily conserved role of calcineurin in phosphodegron-dependent degradation of phosphodiesterase 4D. 
  • FKBP12 dimerization mutations effect FK506 binding and differentially alter calcineurin inhibition in the human pathogen Aspergillus fumigatus. 
  • FKBP12-Dependent Inhibition of Calcineurin Mediates Immunosuppressive Antifungal Drug Action in Malassezia. 
  • Harnessing calcineurin as a novel anti-infective agent against invasive fungal infections. 
  • Harnessing calcineurin-FK506-FKBP12 crystal structures from invasive fungal pathogens to develop antifungal agents. 
  • Identification and characterization of a highly conserved calcineurin binding protein, CBP1/calcipressin, in Cryptococcus neoformans. 
  • Immunocompetent T-cells with a memory-like phenotype are the dominant cell type following antibody-mediated T-cell depletion. 
  • Immunosuppressive and nonimmunosuppressive cyclosporine analogs are toxic to the opportunistic fungal pathogen Cryptococcus neoformans via cyclophilin-dependent inhibition of calcineurin. 
  • Immunotherapy with tacrolimus (FK506) does not select for resistance to calcineurin inhibitors in Candida albicans isolates from liver transplant patients. 
  • In Vitro and In Vivo Assessment of FK506 Analogs as Novel Antifungal Drug Candidates. 
  • In vitro interactions between antifungals and immunosuppressants against Aspergillus fumigatus isolates from transplant and nontransplant patients. 
  • In vitro interactions between antifungals and immunosuppressants against Aspergillus fumigatus. 
  • Induction immunosuppression in liver transplantation: a review. 
  • Influence of long chain polyunsaturated fatty acids and ornithine concentrations on complications after renal transplant. 
  • Leveraging Fungal and Human Calcineurin-Inhibitor Structures, Biophysical Data, and Dynamics To Design Selective and Nonimmunosuppressive FK506 Analogs. 
  • Multiple domains of MCIP1 contribute to inhibition of calcineurin activity. 
  • Myocyte-enriched calcineurin-interacting protein, MCIP1, inhibits cardiac hypertrophy in vivo. 
  • Neurotrophins and netrins require calcineurin/NFAT signaling to stimulate outgrowth of embryonic axons. 
  • No evidence of increased cancer incidence in children using topical tacrolimus for atopic dermatitis. 
  • Optimization of de novo belatacept-based immunosuppression administered to renal transplant recipients. 
  • Outcomes at 3 years of a prospective pilot study of Campath-1H and sirolimus immunosuppression for renal transplantation. 
  • Phosphorylation of Calcineurin at a novel serine-proline rich region orchestrates hyphal growth and virulence in Aspergillus fumigatus. 
  • Physiologic importance of protein phosphatase inhibitors. 
  • Polyhexamethylene biguanide and calcineurin inhibitors as novel antifungal treatments for Aspergillus keratitis. 
  • Potentiation of CD3-induced expression of the linker for activation of T cells (LAT) by the calcineurin inhibitors cyclosporin A and FK506. 
  • Predictors of immune reconstitution syndrome in organ transplant recipients with cryptococcosis: implications for the management of immunosuppression. 
  • Prescription Treatment Options. 
  • Protein phosphatases mediate depotentiation induced by high-intensity theta-burst stimulation. 
  • Rapamycin (sirolimus) for treatment of chronic graft-versus-host disease. 
  • Renal transplantation using belatacept without maintenance steroids or calcineurin inhibitors. 
  • Renaming the DSCR1/Adapt78 gene family as RCAN: regulators of calcineurin. 
  • Role of low-dose calcineurin inhibitor regimens in pediatric kidney transplantation. 
  • Safety events in kidney transplant recipients: results from the folic Acid for vascular outcome reduction in transplant trial. 
  • Safety of Everolimus With Reduced Calcineurin Inhibitor Exposure in De Novo Kidney Transplants: An Analysis From the Randomized TRANSFORM Study. 
  • Secretion of FK506/FK520 and rapamycin by Streptomyces inhibits the growth of competing Saccharomyces cerevisiae and Cryptococcus neoformans. 
  • Signaling cascades as drug targets in model and pathogenic fungi. 
  • Sirolimus conversion regimen versus continued calcineurin inhibitors in liver allograft recipients: a randomized trial. 
  • Structure-Guided Synthesis of FK506 and FK520 Analogs with Increased Selectivity Exhibit In Vivo Therapeutic Efficacy against Cryptococcus. 
  • Synergistic antifungal activities of bafilomycin A(1), fluconazole, and the pneumocandin MK-0991/caspofungin acetate (L-743,873) with calcineurin inhibitors FK506 and L-685,818 against Cryptococcus neoformans. 
  • Synergistic effect of calcineurin inhibitors and fluconazole against Candida albicans biofilms. 
  • Tailored use of belatacept in adolescent kidney transplantation. 
  • Targeted inhibition of calcineurin in pressure-overload cardiac hypertrophy. Preservation of systolic function. 
  • Targeting Calcium Release-activated Calcium Channel Is Not Sufficient to Prevent Rejection in Nonhuman Primate Kidney Transplantation. 
  • Teaching old drugs new tricks: reincarnating immunosuppressants as antifungal drugs. 
  • The C2 domain protein Cts1 functions in the calcineurin signaling circuit during high-temperature stress responses in Cryptococcus neoformans. 
  • The Cryptococcus neoformans MAP kinase Mpk1 regulates cell integrity in response to antifungal drugs and loss of calcineurin function. 
  • The case for treatment of monogenic SRNS with calcineurin inhibitors. 
  • The role of modulatory calcineurin-interacting proteins in calcineurin signaling. 
  • Use of Everolimus After Multivisceral Transplantation: A Report of Two Cases. 
  • Use of protein phosphatase inhibitors. 
  • Use of protein phosphatase inhibitors.